pimozide has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, BH; Chen, BY; Chen, SB; Chen, XC; Fang, Y; Fei, MY; Gu, JJ; Gui, AL; Hu, CL; Jiang, SY; Jiang, YL; Li, XY; Li, ZJ; Liu, P; Sun, XJ; Wang, L; Wang, Y; Wu, JC; Xu, CH; Xue, K; Yang, L; Yu, BH; Yu, PC; Zhang, JY; Zhang, QL; Zong, LJ | 1 |
1 other study(ies) available for pimozide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mice; Pimozide; Rituximab; Ubiquitin-Specific Proteases | 2023 |